ArticleIndian journal of ophthalmology2020
Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema.
Article in Indian journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis.Systematic reviews · 2023Pooled it
- Safety, Tolerability and PK Characteristics of RM301B Eye Drops: A Single-Centre, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial.Advances in therapy · 2026Trial
- Impact of a structured patient engagement program on treatment adherence, injection persistence, and visual outcomes in real-world anti-VEGF therapy for neovascular age-related macular degeneration.BMC ophthalmology · 2026Observational
- Real-World Persistence with Anti-VEGF Therapy in Neovascular Age-related Macular Degeneration.Ophthalmology and therapy · 2026Article
- Compliance to intravitreal anti-vascular endothelial growth factors for treatment of retinal diseases in Nigerians: a retrospective multicenter study.BMC ophthalmology · 2026Article
- Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India.Indian journal of ophthalmology · 2026Review
- Optimizing the invisible costs of anti-VEGF: The road to regularity.Indian journal of ophthalmology · 2026Review
- Neovascular age-related macular degeneration management - Beyond anti-VEGF.Indian journal of ophthalmology · 2026Review
- Article
- Persistent Vision Loss of Eyes Lost to Follow-Up with Diabetic Macular Edema Receiving Intravitreal Anti-VEGF Therapy.Ophthalmology science · 2026Article
- Lost to follow-up while undergoing intravitreal injection therapy: barriers to adherence in a real-world setting.International journal of retina and vitreous · 2026Article
- Long-acting fenofibrate-loaded microparticles for treating retinal disorders.International journal of pharmaceutics · 2026Article
- Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study.Scientific reports · 2026Article
- FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.Eye (London, England) · 2025Article
- Nonadherence to anti-VEGF intravitreal injections in patients with diabetic macular edema : The names of the authors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Review
- Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).Eye (London, England) · 2025Observational
- Meta-analysis: long/short-term efficacy of anti-VEGF vs. panretinal photocoagulation in preventing severe complications in proliferative diabetic retinopathy.International journal of retina and vitreous · 2025Review
- Article
- CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the rate of compliance and the reasons for loss to follow-up in Indian patients with diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) being treated with anti-vascular endothelial growth factor (VEGF) therapy.
methodsThis was a retrospective single-center study. Patients with DME, AMD, or RVO were eligible if they initiated anti-VEGF therapy between January 2013 and December 2017. Patients' data were obtained from hospital electronic records, including the number of injections received, visits, details of follow-up, missed appointments, and reasons for loss to follow-up (>365 days).
resultsA total of 648 patients were eligible for the study, of which 334 (51.54%) patients were lost to follow-up. Overall, 343 (64.96%) were males and the overall mean (SD) age was 66.40 (7.44) years. A total of 376 (58.0%) patients had a history of diabetes and 364 (56.2%) patients had a history of hypertension. Further, 127 (38.0), 112 (33.5), and 95 (28.4) had DME, AMD, and RVO, respectively and were lost to follow-up. The most commonly reported reason for loss to follow-up was "non-affordability" (n = 120; 41.1%) followed by "no improvement in vision" (n = 83; 28.4%). "No improvement in vision" (42.2%) and "non-affordability" (37.5%) were higher among patients with DME. No association was found in gender- and treatment-wise distribution of reasons for loss to follow-up.
conclusionThe results showed that around half of the patients with DME, AMD, and RVO were lost to follow-up to intravitreal anti-VEGF therapy, and the most common factors were "non-affordability" and "no improvement in vision."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.